<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928746</url>
  </required_header>
  <id_info>
    <org_study_id>244.2507</org_study_id>
    <nct_id>NCT00928746</nct_id>
  </id_info>
  <brief_title>Actuation Indicator Trial in Patients With COPD</brief_title>
  <official_title>ATROVENT HFA Actuation Indicator Open-Label Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the performance, accuracy, and handling of
      the actuation indicator in patients with COPD. The actuation indicator is integrated into
      mouthpiece of the ipratropium bromide HFA inhalation aerosol device. As part of Boehringer
      Ingelheim's program to qualify an actuation indicator for use with the ipratropium bromide
      HFA inhalation aerosol device, this study is intended to complement the results from the
      ongoing in-vitro studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Actuations Registered by the Actuation Indicator</measure>
    <time_frame>21 Days</time_frame>
    <description>This outcome measure presents the number of actuations (doses) of medication used in the specific time frame as measured by the actuation indicator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Actuations Dispensed</measure>
    <time_frame>21 Days</time_frame>
    <description>Actuations dispensed is determined by the weight differential of the canister over the course of the study divided by the shot weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference Between the Number of Actuations Registered by Actuation Indicator Versus Actuations Dispensed</measure>
    <time_frame>21 Days</time_frame>
    <description>Difference between the number of actuations registered by the actuation indicator and the number of actuations dispensed (calculated using weight differential and shot weight)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Actuations Recorded on Patient Diary</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actuations Based on Advancing the Actuation Indicator</measure>
    <time_frame>21 Days</time_frame>
    <description>Actuations based on advancing the actuation indicator to a zero reading or to the next increment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actuations Registered by the Actuation Indicator and Read by Site Coordinator</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between the Number of Actuations Recorded on Patient Diary Versus Actuations Dispensed</measure>
    <time_frame>21 Days</time_frame>
    <description>Difference between the number of actuations recorded on patient diary and the number of actuations dispensed (calculated using weight differential and shot weight)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between the Number of Actuations Based on Advancing Actuation Indicator Versus Actuations Dispensed</measure>
    <time_frame>21 Days</time_frame>
    <description>Difference between the number of actuations based on advancing the actuation indicator to a zero reading or to the next increment and the number of actuations dispensed (calculated using weight differential and shot weight)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between the Number of Actuations Registered by the Actuation Indicator and Read by Site Coordinator Versus Actuations Dispensed</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported Problems With Use of Inhaler With Integrated Dose Counter According to Patient Handling Questionnaire</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported Problems With Seeing Red Warning Indicating Inhaler Near End of Recommended Doses According to Patient Handling Questionnaire</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported Problems With Inhaler and Dose Counter Performing as Expected Based on Instructions According to Patient Handling Questionnaire</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported Satisfaction With Performance of the Dose Counter for Indicating Approximately How Many Doses Remain in Inhaler According to Patient Handling Questionnaire</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported Satisfaction That the Dose Counter Worked Reliably According to Patient Handling Questionnaire</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported Satisfaction With Ease of Use of the Dose Counter According to Patient Handling Questionnaire</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported Satisfaction With Dose Counter in the Mouthpiece of the Inhaler According to Patient Handling Questionnaire</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Having Any Additional Comments According to Patient Handling Questionnaire</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>ATROVENT 42mcg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ipratropium bromide</intervention_name>
    <arm_group_label>ATROVENT 42mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A diagnosis of COPD based on medical history at a severity to require maintenance
             treatment with a bronchodilator

          2. Male or female patients 40 years of age or older

          3. A smoking history of more than ten pack-years. A pack-year is defined as the
             equivalent of smoking one pack of 20 cigarettes per day for a year

          4. Must be able to use the study MDI with the mouthpiece containing actuation indicator

        Exclusion Criteria:

          1. Significant diseases other than COPD are excluded. A significant disease is defined as
             a disease which in the opinion of the investigator may either put the patient at risk
             because of participation in the study or a disease which may influence the results of
             the study or the patient's ability to participate in the study

          2. Malignancy for which the patient has undergone resection, radiation therapy or
             chemotherapy within the last three months. Patients with treated basal cell carcinoma
             are allowed

          3. History of asthma

          4. Significant history active alcohol or drug abuse

          5. Known active tuberculosis

          6. Known narrow-angle glaucoma

          7. Current significant psychiatric disorders

          8. Pregnant or nursing women or women of childbearing potential not using a medically
             approved means of contraception (i.e., oral contraceptives, intrauterine devices or
             diaphragm with spermicide, or NorplantÂ®)

          9. Known hypersensitivity to anticholinergic drugs, any other component of the
             ipratropium bromide, HFA-134a or MDI components

         10. Previous participation in this trial

         11. Patients who are currently participating in another trial and/or who have received
             investigational drug within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>244.2507.0107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>244.2507.0106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>244.2507.0102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>244.2507.0104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>244.2507.0105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>244.2507.0103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>244.2507.0101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <results_first_submitted>August 4, 2010</results_first_submitted>
  <results_first_submitted_qc>September 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 28, 2010</results_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ATROVENT 42mcg</title>
          <description>ATROVENT HFA (42 mcg)- Oral inhalation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients who were entered into this study and documented to have taken at least one dose of study medication (treated set).</population>
      <group_list>
        <group group_id="B1">
          <title>ATROVENT 42mcg</title>
          <description>ATROVENT HFA (42 mcg)- Oral inhalation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.7" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Does not drink alcohol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks alcohol - should not interfere with trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smoke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.2" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.8" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Actuations Registered by the Actuation Indicator</title>
        <description>This outcome measure presents the number of actuations (doses) of medication used in the specific time frame as measured by the actuation indicator</description>
        <time_frame>21 Days</time_frame>
        <population>The primary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations group</description>
          </group>
        </group_list>
        <measure>
          <title>Actuations Registered by the Actuation Indicator</title>
          <description>This outcome measure presents the number of actuations (doses) of medication used in the specific time frame as measured by the actuation indicator</description>
          <population>The primary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>Count</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" spread="19.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Actuations Dispensed</title>
        <description>Actuations dispensed is determined by the weight differential of the canister over the course of the study divided by the shot weight</description>
        <time_frame>21 Days</time_frame>
        <population>The primary analysis was performed using the Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg - Oral inhalation) - 180 Actuations group</description>
          </group>
        </group_list>
        <measure>
          <title>Actuations Dispensed</title>
          <description>Actuations dispensed is determined by the weight differential of the canister over the course of the study divided by the shot weight</description>
          <population>The primary analysis was performed using the Full Analysis Set (FAS)</population>
          <units>Count</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.77" spread="20.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference Between the Number of Actuations Registered by Actuation Indicator Versus Actuations Dispensed</title>
        <description>Difference between the number of actuations registered by the actuation indicator and the number of actuations dispensed (calculated using weight differential and shot weight)</description>
        <time_frame>21 Days</time_frame>
        <population>The primary analysis was performed using the Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between the Number of Actuations Registered by Actuation Indicator Versus Actuations Dispensed</title>
          <description>Difference between the number of actuations registered by the actuation indicator and the number of actuations dispensed (calculated using weight differential and shot weight)</description>
          <population>The primary analysis was performed using the Full Analysis Set (FAS)</population>
          <units>Count</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="9.8" lower_limit="1.29" upper_limit="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actuations Recorded on Patient Diary</title>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Actuations Recorded on Patient Diary</title>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>Count</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" spread="20.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actuations Based on Advancing the Actuation Indicator</title>
        <description>Actuations based on advancing the actuation indicator to a zero reading or to the next increment</description>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Actuations Based on Advancing the Actuation Indicator</title>
          <description>Actuations based on advancing the actuation indicator to a zero reading or to the next increment</description>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>Count</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" spread="19.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actuations Registered by the Actuation Indicator and Read by Site Coordinator</title>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Actuations Registered by the Actuation Indicator and Read by Site Coordinator</title>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>Count</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164" spread="19.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between the Number of Actuations Recorded on Patient Diary Versus Actuations Dispensed</title>
        <description>Difference between the number of actuations recorded on patient diary and the number of actuations dispensed (calculated using weight differential and shot weight)</description>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between the Number of Actuations Recorded on Patient Diary Versus Actuations Dispensed</title>
          <description>Difference between the number of actuations recorded on patient diary and the number of actuations dispensed (calculated using weight differential and shot weight)</description>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>Count</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" spread="18.85" lower_limit="3.11" upper_limit="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between the Number of Actuations Based on Advancing Actuation Indicator Versus Actuations Dispensed</title>
        <description>Difference between the number of actuations based on advancing the actuation indicator to a zero reading or to the next increment and the number of actuations dispensed (calculated using weight differential and shot weight)</description>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between the Number of Actuations Based on Advancing Actuation Indicator Versus Actuations Dispensed</title>
          <description>Difference between the number of actuations based on advancing the actuation indicator to a zero reading or to the next increment and the number of actuations dispensed (calculated using weight differential and shot weight)</description>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>Count</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="9.3" lower_limit="0.18" upper_limit="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between the Number of Actuations Registered by the Actuation Indicator and Read by Site Coordinator Versus Actuations Dispensed</title>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between the Number of Actuations Registered by the Actuation Indicator and Read by Site Coordinator Versus Actuations Dispensed</title>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>Count</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="9.8" lower_limit="2.06" upper_limit="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported Problems With Use of Inhaler With Integrated Dose Counter According to Patient Handling Questionnaire</title>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Problems With Use of Inhaler With Integrated Dose Counter According to Patient Handling Questionnaire</title>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported Problems With Seeing Red Warning Indicating Inhaler Near End of Recommended Doses According to Patient Handling Questionnaire</title>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Problems With Seeing Red Warning Indicating Inhaler Near End of Recommended Doses According to Patient Handling Questionnaire</title>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported Problems With Inhaler and Dose Counter Performing as Expected Based on Instructions According to Patient Handling Questionnaire</title>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Problems With Inhaler and Dose Counter Performing as Expected Based on Instructions According to Patient Handling Questionnaire</title>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported Satisfaction With Performance of the Dose Counter for Indicating Approximately How Many Doses Remain in Inhaler According to Patient Handling Questionnaire</title>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Satisfaction With Performance of the Dose Counter for Indicating Approximately How Many Doses Remain in Inhaler According to Patient Handling Questionnaire</title>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported Satisfaction That the Dose Counter Worked Reliably According to Patient Handling Questionnaire</title>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Satisfaction That the Dose Counter Worked Reliably According to Patient Handling Questionnaire</title>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported Satisfaction With Ease of Use of the Dose Counter According to Patient Handling Questionnaire</title>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Satisfaction With Ease of Use of the Dose Counter According to Patient Handling Questionnaire</title>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported Satisfaction With Dose Counter in the Mouthpiece of the Inhaler According to Patient Handling Questionnaire</title>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Satisfaction With Dose Counter in the Mouthpiece of the Inhaler According to Patient Handling Questionnaire</title>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Having Any Additional Comments According to Patient Handling Questionnaire</title>
        <time_frame>21 Days</time_frame>
        <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>ATROVENT 42mcg</title>
            <description>ATROVENT HFA (42 mcg- Oral inhalation) - 180 Actuations Group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Having Any Additional Comments According to Patient Handling Questionnaire</title>
          <population>This secondary analysis was performed using the Full Analysis Set (FAS).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 21 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ATROVENT 42mcg</title>
          <description>ATROVENT HFA (42 mcg)- Oral inhalation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

